deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01564537

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Sponsor: Takeda

Conditions Refractory Multiple Myeloma Relapsed Multiple Myeloma
Interventions Dexamethasone Ixazomib Lenalidomide Placebo
Updated 16 times since 2017 Last updated: Feb 7, 2023 Started: Aug 1, 2012 Primary completion: Oct 1, 2014 Completion: Feb 8, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Refractory Multiple Myeloma and Relapsed Multiple Myeloma, this trial is completed. The trial is conducted by Takeda and has accumulated 16 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Dec 2019 · 13 months · monthly snapshot~Dec 2019 – ~Nov 2020 · 11 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 21 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Apr 2022 — Apr 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Jan 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

▶ Show 11 earlier versions

  1. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Dec 2019 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Nov 2018 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Aug 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE3

  9. May 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE3

  10. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE3

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Takeda
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Berkeley, United States , Boston, United States , Buffalo, United States , Calgary, Canada , Charleston, United States , Chicago, United States , Edmonton, Canada , Fayetteville, United States , Gainesville, United States and 13 more locations